Should I buy or sell Organon & Co. stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Organon & Co. in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" OGN shares. View OGN analyst ratings or view top-rated stocks .

What is Organon & Co.'s stock price target for 2024?

4 Wall Street research analysts have issued 1-year target prices for Organon & Co.'s shares. Their OGN share price targets range from $18.00 to $28.00. On average, they anticipate the company's share price to reach $21.80 in the next twelve months. This suggests a possible upside of 23.1% from the stock's current price. View analysts price targets for OGN or view top-rated stocks among Wall Street analysts .

How have OGN shares performed in 2024?

Organon & Co.'s stock was trading at $14.42 at the beginning of the year. Since then, OGN stock has increased by 22.8% and is now trading at $17.71. View the best growth stocks for 2024 here .

When is Organon & Co.'s next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our OGN earnings forecast .

How can I listen to Organon & Co.'s earnings call?

Organon & Co. will be holding an earnings conference call on Thursday, May 2nd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link .

How were Organon & Co.'s earnings last quarter?

Organon & Co. (NYSE:OGN) posted its earnings results on Thursday, February, 15th. The company reported $0.87 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.73 by $0.14. The company earned $1.60 billion during the quarter, compared to the consensus estimate of $1.55 billion. Organon & Co. had a negative trailing twelve-month return on equity of 212.00% and a net margin of 16.33%.

How often does Organon & Co. pay dividends? What is the dividend yield for Organon & Co.?

Organon & Co. declared a quarterly dividend on Thursday, February 15th. Investors of record on Monday, February 26th will be given a dividend of $0.28 per share on Thursday, March 14th. This represents a $1.12 dividend on an annualized basis and a yield of 6.32%. The ex-dividend date is Friday, February 23rd. Read our dividend analysis for OGN .

Is Organon & Co. a good dividend stock?

Organon & Co. (NYSE:OGN) pays an annual dividend of $1.12 per share and currently has a dividend yield of 6.42%. OGN has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 28.00%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, OGN will have a dividend payout ratio of 26.67% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for OGN .

What ETFs hold Organon & Co.'s stock?

ETFs with the largest weight of Organon & Co. (NYSE:OGN) stock in their portfolio include Invesco S&P Spin-Off ETF (CSD) , SPDR S&P Pharmaceuticals ETF (XPH) , Invesco S&P SmallCap Health Care ETF (PSCH) , Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) , WBI Power Factor High Dividend ETF (WBIY) , Invesco S&P SmallCap High Dividend Low Volatility ETF (XSHD) , Emerge EMPWR Sustainable Dividend Equity ETF (EMCA) and Invesco S&P 500 High Dividend Low Volatility ETF (SPHD) .

What guidance has Organon & Co. issued on next quarter's earnings?

Organon & Co. updated its FY 2024 earnings guidance on Friday, February, 16th. The company provided EPS guidance of for the period. The company issued revenue guidance of $6.2 billion-$6.5 billion, compared to the consensus revenue estimate of $6.4 billion.

Who are Organon & Co.'s major shareholders?

Organon & Co.'s stock is owned by a number of retail and institutional investors. Top institutional shareholders include Gilman Hill Asset Management LLC (0.26%), Sound Income Strategies LLC (0.21%), Douglas Lane & Associates LLC (0.19%), Los Angeles Capital Management LLC (0.07%), Alaska Permanent Fund Corp (0.06%) and Radnor Capital Management LLC (0.02%). Insiders that own company stock include Kirke Weaver and Ma Fatima Francisco . View institutional ownership trends .

How do I buy shares of Organon & Co.?

Shares of OGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSE:OGN

Organon & Co. (OGN) Stock Price, News & Analysis

→ A.I. “Perfect Storm” Could Send THESE Stocks Sky High (From InvestorPlace) (Ad)

Free OGN Stock Alerts

$17.71

+0.26 (+1.49%)

(As of 04/15/2024 ET)

Compare

Today's Range: $17.58
▼
$17.92
50-Day Range: $16.13
▼
$18.80
52-Week Range: $10.84
▼
$24.79

Volume: 2.66 million shs
Average Volume: 2.78 million shs
Market Capitalization: $4.53 billion

P/E Ratio: 4.43
Dividend Yield: 6.32%
Price Target: $21.80

Get Organon & Co. alerts:

Organon & Co. MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 23.1% Upside
$21.80 Price Target
Short Interest: Bearish
4.28% of Float Sold Short
Dividend Strength: Strong
Based on Four Factors
Sustainability: -2.37
Upright™ Environmental Score
News Sentiment: 0.90
Based on 2 Articles This Week
Insider Trading: Acquiring Shares
$49,939 Bought Last Quarter
Proj. Earnings Growth: 2.94%
From $4.08 to $4.20 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.71 out of 5 stars

Medical Sector

55th out of 929 stocks

Pharmaceutical Preparations Industry

19th out of 422 stocks

2.3

Analyst's Opinion

Consensus Rating
Organon & Co. has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Organon & Co. has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
4.28% of the float of Organon & Co. has been sold short.
Short Interest Ratio / Days to Cover
Organon & Co. has a short interest ratio ("days to cover") of 4.
Change versus previous month
Short interest in Organon & Co. has recently increased by 7.90%, indicating that investor sentiment is decreasing significantly.

3.3

Dividend Strength

Dividend Leadership
Organon & Co. is a leading dividend payer. It pays a dividend yield of 6.42%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
Organon & Co. does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Organon & Co. is 28.00%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Organon & Co. will have a dividend payout ratio of 26.67% next year. This indicates that Organon & Co. will be able to sustain or increase its dividend.

3.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Organon & Co. has received a 48.54% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Ezetimibe", "Contraceptive implants", "Losartan", "Montelukast", and "Contraceptives" products. See details.
Environmental Sustainability
The Environmental Impact score for Organon & Co. is -2.37.

2.2

News and Social Media Coverage

News Sentiment
Organon & Co. has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Organon & Co. this week, compared to 4 articles on an average week.
Search Interest
Only 45 people have searched for OGN on MarketBeat in the last 30 days. This is a decrease of -12% compared to the previous 30 days.
MarketBeat Follows
Only 13 people have added Organon & Co. to their MarketBeat watchlist in the last 30 days. This is a decrease of -13% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Organon & Co. insiders have bought more of their company's stock than they have sold. Specifically, they have bought $49,939.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 1.17% of the stock of Organon & Co. is held by insiders.
Percentage Held by Institutions
77.43% of the stock of Organon & Co. is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1

Earnings and Valuation

Earnings Growth
Earnings for Organon & Co. are expected to grow by 2.94% in the coming year, from $4.08 to $4.20 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Organon & Co. is 4.43, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 142.21.
Price to Earnings Ratio vs. Sector
The P/E ratio of Organon & Co. is 4.43, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 248.92.
Price to Earnings Growth Ratio
Organon & Co. has a PEG Ratio of 0.83. PEG Ratios below 1 indicate that a company could be undervalued.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

And you could go along for the ride if you make this one simple move.

About Organon & Co. Stock (NYSE:OGN)

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.

OGN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

OGN Stock News Headlines

April 8, 2024 | businesswire.com

Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024

April 8, 2024 | businesswire.com

Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints

April 16, 2024 | InvestorPlace (Ad)

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

March 17, 2024 | nasdaq.com

OGN Quantitative Stock Analysis

March 8, 2024 | finance.yahoo.com

On International Women's Day, Organon Canada is encouraging businesses to Invest in HER and help address gender inequities through women's health

March 7, 2024 | investorplace.com

Turn $500 into a Fortune: 3 Top Stock Picks for March's Million-Dollar Rally

March 6, 2024 | investing.com

Organon & Co (OGN)

March 5, 2024 | finance.yahoo.com

Organon's Valuation Is Not Expensive

April 16, 2024 | InvestorPlace (Ad)

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

February 26, 2024 | investorplace.com

Under the Radar: 3 Overlooked Stocks Ready to Dominate the Market

February 23, 2024 | seekingalpha.com

Organon Stock Is Still Worth A Look

February 20, 2024 | finance.yahoo.com

Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary

February 20, 2024 | businesswire.com

Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary

February 16, 2024 | seekingalpha.com

Organon Q4 And Full Year 2023 Earnings Review - Positive Updates At Last

February 16, 2024 | msn.com

Organon & Co. Earnings Transcript (NYSE:OGN)

February 16, 2024 | markets.businessinsider.com

Maintaining Sell Rating on Organon: Short-Term Gains Overshadowed by Long-Term Strategy Concerns

February 16, 2024 | finance.yahoo.com

Organon & Co. (NYSE:OGN) Q4 2023 Earnings Call Transcript

February 15, 2024 | msn.com

Why Is Women Health-Focused Organon Stock Trading Higher On Thursday?

February 15, 2024 | finance.yahoo.com

Organon & Co (OGN) Reports Steady Growth Amidst Market Challenges

February 15, 2024 | seekingalpha.com

Organon & Co. 2023 Q4 - Results - Earnings Call Presentation

February 15, 2024 | finance.yahoo.com

Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023

February 15, 2024 | businesswire.com

Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023

February 14, 2024 | msn.com

Do You Believe That Organon & Co. (OGN) is a Compelling Prospect for Long-Term, Patient Investors?

February 1, 2024 | finance.yahoo.com

Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 15, 2024

January 30, 2024 | benzinga.com

Organon Stock (NYSE:OGN), Guidance and Forecast

January 28, 2024 | finance.yahoo.com

Recent uptick might appease Organon & Co. (NYSE:OGN) institutional owners after losing 41% over the past year

January 22, 2024 | benzinga.com

Looking Into Organon's Recent Short Interest

See More Headlines

Receive OGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Organon & Co. and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/15/2024
Ex-Dividend for 3/14 Dividend: 2/23/2024
Dividend Payable: 3/14/2024
Today: 4/16/2024
Next Earnings (Confirmed): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NYSE:OGN
CUSIP: N/A
CIK: 1821825
Web: www.organon.com
Phone: 551-430-6900
Fax: N/A
Employees: 10,000
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $21.80
High Stock Price Target: $28.00
Low Stock Price Target: $18.00
Potential Upside/Downside: +23.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): $4.00
Trailing P/E Ratio: 4.43
Forward P/E Ratio: 4.34
P/E Growth: 0.83
Net Income: $1.02 billion
Net Margins: 16.33%
Pretax Margin: 10.75%
Return on Equity: -212.00%
Return on Assets: 9.23%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.54
Quick Ratio: 1.09

Sales & Book Value

Annual Sales: $6.26 billion
Price / Sales: 0.72
Cash Flow: $5.10 per share
Price / Cash Flow: 3.47
Book Value: ($0.27) per share
Price / Book: -65.59

Miscellaneous

Outstanding Shares: 255,640,000
Free Float: 252,647,000
Market Cap: $4.53 billion
Optionable: Not Optionable
Beta: 0.82

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Mr. Kevin Ali (Age 64)
CEO & Director
Comp: $3.96M
Mr. Matthew M. Walsh (Age 57)
Executive VP & CFO
Comp: $1.84M
Ms. Susanne Gabriele Fiedler (Age 55)
Executive VP & Chief Commercial Officer
Comp: $1.44M
Mr. Joseph T. Morrissey Jr. (Age 58)
Executive VP and Head of Manufacturing & Supply
Comp: $1.54M
Ms. Rachel A. Stahler (Age 48)
Executive VP & Chief Information Officer
Ms. Jennifer Halchak
Head of Investor Relations
Mr. Kirke Weaver (Age 50)
Executive VP, General Counsel & Corporate Secretary
Ms. Susan O'Neal
Chief Ethics & Compliance Officer
Ms. Rebecca Lowell Edwards
Chief Communications Officer
Mr. Daniel Karp (Age 46)
Chief Business Development Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

OGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Organon & Co. stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Organon & Co. in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" OGN shares.
View OGN analyst ratings or view top-rated stocks.
What is Organon & Co.'s stock price target for 2024?: 4 Wall Street research analysts have issued 1-year target prices for Organon & Co.'s shares. Their OGN share price targets range from $18.00 to $28.00. On average, they anticipate the company's share price to reach $21.80 in the next twelve months. This suggests a possible upside of 23.1% from the stock's current price.
View analysts price targets for OGN or view top-rated stocks among Wall Street analysts.
How have OGN shares performed in 2024?: Organon & Co.'s stock was trading at $14.42 at the beginning of the year. Since then, OGN stock has increased by 22.8% and is now trading at $17.71.
View the best growth stocks for 2024 here.
When is Organon & Co.'s next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our OGN earnings forecast.
How can I listen to Organon & Co.'s earnings call?: Organon & Co. will be holding an earnings conference call on Thursday, May 2nd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.
How were Organon & Co.'s earnings last quarter?: Organon & Co. (NYSE:OGN) posted its earnings results on Thursday, February, 15th. The company reported $0.87 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.73 by $0.14. The company earned $1.60 billion during the quarter, compared to the consensus estimate of $1.55 billion. Organon & Co. had a negative trailing twelve-month return on equity of 212.00% and a net margin of 16.33%.

How often does Organon & Co. pay dividends? What is the dividend yield for Organon & Co.?: Organon & Co. declared a quarterly dividend on Thursday, February 15th. Investors of record on Monday, February 26th will be given a dividend of $0.28 per share on Thursday, March 14th. This represents a $1.12 dividend on an annualized basis and a yield of 6.32%. The ex-dividend date is Friday, February 23rd.
Read our dividend analysis for OGN.
Is Organon & Co. a good dividend stock?: Organon & Co. (NYSE:OGN) pays an annual dividend of $1.12 per share and currently has a dividend yield of 6.42%. OGN has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 28.00%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, OGN will have a dividend payout ratio of 26.67% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for OGN.
What ETFs hold Organon & Co.'s stock?: ETFs with the largest weight of Organon & Co. (NYSE:OGN) stock in their portfolio include Invesco S&P Spin-Off ETF (CSD), SPDR S&P Pharmaceuticals ETF (XPH), Invesco S&P SmallCap Health Care ETF (PSCH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), WBI Power Factor High Dividend ETF (WBIY), Invesco S&P SmallCap High Dividend Low Volatility ETF (XSHD), Emerge EMPWR Sustainable Dividend Equity ETF (EMCA) and Invesco S&P 500 High Dividend Low Volatility ETF (SPHD).
What guidance has Organon & Co. issued on next quarter's earnings?: Organon & Co. updated its FY 2024 earnings guidance on Friday, February, 16th. The company provided EPS guidance of for the period. The company issued revenue guidance of $6.2 billion-$6.5 billion, compared to the consensus revenue estimate of $6.4 billion.
Who are Organon & Co.'s major shareholders?: Organon & Co.'s stock is owned by a number of retail and institutional investors. Top institutional shareholders include Gilman Hill Asset Management LLC (0.26%), Sound Income Strategies LLC (0.21%), Douglas Lane & Associates LLC (0.19%), Los Angeles Capital Management LLC (0.07%), Alaska Permanent Fund Corp (0.06%) and Radnor Capital Management LLC (0.02%). Insiders that own company stock include Kirke Weaver and Ma Fatima Francisco.
View institutional ownership trends.
How do I buy shares of Organon & Co.?: Shares of OGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:OGN) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Organon & Co. (OGN) Stock Price, News & Analysis

Organon & Co. MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Organon & Co. Stock (NYSE:OGN)

OGN Stock Price History

OGN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

OGN Stock Analysis - Frequently Asked Questions

Overall MarketRank^™